US 10,457,711: What do the claims really cover in Dermatophagoides farinae allergy?

US Patent 10,457,711 claims two related method inventions centered on a specific Dermatophagoides farinae protein “SEQ ID NO:2” (and close variants and fragments) for: (1) preventing or treating a D. farinae allergic disease, and (2) detecting an allergic state by administering the same antigen(s) and measuring the subject’s allergic response. The independent scope is broad on sequence freedom (substitutions/deletions/additions; and “≥90% identity”) and broad on fragment length (10 to 34 amino acids), while still constrained by a functional requirement that the protein variants retain Dermatophagoides allergenicity.

What do Claims 1 and 2 cover?

Claim 1 (treatment / prevention)

A method for preventing or treating an allergic disease caused by Dermatophagoides farinae, comprising administering to a patient one of the following:

(a) a protein comprising the amino acid sequence of SEQ ID NO:2
(b) a protein with 1 to 10 amino acid substitutions and/or deletions relative to SEQ ID NO:2, and/or one or several amino acids added, with allergenicity of D. farinae
(c) a protein with ≥90% identity to the SEQ ID NO:2 amino acid sequence and with allergenicity of D. farinae
Fragment peptides: a fragment comprising 10 to 34 amino acid residues of (a), (b), or (c)

The claim is drafted to capture both:

full-length antigen proteins (a, b, c), and
shorter epitopic forms (10-34mers)

Claim 2 (detection)

A method for detecting an allergic disease caused by D. farinae, comprising:

administering to a test subject one of the same protein/fragment categories (a, b, c or 10-34 residues), and
measuring an allergic state of the test subject

Claims 1 and 2 share the same antigen selection core; the difference is the clinical endpoint.

Dependent claims 3-10

These only specify administration to the patient (claims 3-6) or test subject (claims 7-10), and that the selected antigen is (a), (b), (c), or 10-34 residue fragments.

Where is the real scope, and where is it constrained?

US 10,457,711’s enforceable focus is narrower than the raw structural language might suggest, because the claim uses “allergenicity” as a gate.

Key scope drivers (broad)

Identity threshold: ≥90% identity relative to SEQ ID NO:2 is permissive and will capture many homologs across strains or related allergen family members, depending on what SEQ ID NO:2 is in the specification.
Mutation tolerance: up to 10 substitutions/deletions plus additions allows a wide space of engineered and naturally occurring variants.
Fragment length band: 10 to 34 residues covers typical linear epitope lengths used in peptide allergen assays and immunotherapy formulations.

Key constraints (narrowing)

Functional requirement: variants (b) and (c) must have “allergenicity of D. farinae.” This is a functional property that may limit some off-target homologs even if they meet the sequence yardsticks.
Disease etiology: must be “allergic disease caused by D. farinae.” This ties the use to the relevant allergen source and will matter in both infringement and invalidity narratives (prior art must relate to D. farinae-driven allergy).
Same antigen family: all categories are anchored to SEQ ID NO:2. If SEQ ID NO:2 corresponds to a specific known D. farinae allergen (for example, group 1, group 2, group 3, group 5, group 7, group 21, etc.), that anchor will determine the amount of prior art overlap.

How strong is the infringement risk for competitors?

Competitor exposure depends on whether their product or assay uses:

the specific SEQ ID NO:2 sequence (exact match), or
close variants meeting the 1-10 mutation / add / delete definition or ≥90% identity threshold, and
retains D. farinae allergenicity, and
is used in a method context that maps to “preventing/treating” or “detecting allergic state.”

Infringement mapping framework

Competitor activity	Claim 1 exposure (treat/prevent)	Claim 2 exposure (detect)
Immunotherapy formulation using SEQ ID NO:2 protein	High	N/A
Immunotherapy using engineered SEQ ID NO:2 variants (1-10 changes + allergenicity)	High	N/A
Allergen panel / diagnostic reagent containing 10-34mer epitopes from SEQ ID NO:2	N/A	Medium to high
Diagnostic using recombinant homolog with ≥90% identity to SEQ ID NO:2 and allergenicity	N/A	Medium to high
Non-epitope-containing extracts or complex mixtures (without defined 10-34mers/SEQ ID anchoring)	Lower (depends on whether claim elements are met)	Lower

Where are the weak points for patent validity?

Without the full specification and prosecution history, the cleanest critical lens is claim construction risk against known prior art patterns in allergy patents:

1) Prior art likelihood: D. farinae allergens are well-mined

In the US and global literature, D. farinae proteins and their immunologic roles are extensively documented. Many patents have claimed:

allergen preparations for immunotherapy,
hypoallergenic variants,
peptide-based immunotherapy,
diagnostic assays based on patient immune responses.

US 10,457,711’s novelty must be tied to the particular antigen identity (SEQ ID NO:2) and the specific combination of:

full-length SEQ ID NO:2,
the exact mutation/identity envelope,
and peptide fragment length (10-34) as claimed.

If SEQ ID NO:2 corresponds to a well-established D. farinae allergen already disclosed in earlier patents or publications, then broad claim language risks being invalidated for anticipation or obviousness, unless the patent can point to a specific improvement (for example, a unique epitope mapping or unexpectedly improved immunological behavior).

2) Functional “allergenicity” language invites enablement and clarity challenges

“Allergenicity of D. farinae” is a functional characterization. In many allergy patents, this can be used to broaden coverage but also to invite arguments that:

the claim is not sufficiently definite, or
“allergenicity” is not objectively tied to a reproducible assay method within the claims.

Those attacks are claim-type dependent and hinge on the specification’s description of allergenicity determination. In the claim text alone, the phrase does not lock to a measurement protocol.

3) Broad “≥90% identity” and “1-10 substitutions/deletions + additions” can be overbroad

These mutation definitions are large enough that an examiner or challenger can argue that they sweep in protein variants that would have been obvious from routine engineering once the base sequence is known.

The strongest defense is that the claim is tied to the allergenicity property and that the invention demonstrates that variants within that envelope retain the relevant functional behavior. The weakest position for the patentee is if prior art already taught “sequence-homologous D. farinae allergens and fragments” for therapy or diagnosis.

How does the dual use (treatment vs detection) affect the landscape?

The patent’s two independent claim concepts make it a “two-front” asset:

Claim 1 targets clinical intervention.
Claim 2 targets diagnostic use via antigen administration and “measuring allergic state.”

This pairing matters commercially because it can capture:

immunotherapy products (injection/sublingual/other delivery) built on the sequence,
and diagnostic kits or assays where the sequence (or fragments) is administered and response is measured.

From a landscape perspective, this structure increases the number of potential infringement scenarios. Many allergy patents are limited to one use category (therapeutic compositions or diagnostics), which reduces cross-market exposure.

What is the competitive patent landscape likely to look like around this antigen concept?

Given the claim structure, the relevant competitive landscape generally clusters into three invention archetypes:

Recombinant D. farinae allergen compositions
- Full-length allergens, sometimes with adjuvants.
Engineered hypoallergenic variants
- Mutations designed to reduce IgE binding while maintaining T-cell epitopes.
Peptide-based therapies and diagnostics
- Defined peptide fragments of known allergens, used for immunotherapy or IgE/immune response profiling.

US 10,457,711’s use of both protein and 10-34 amino acid fragments, combined with broad sequence variation thresholds, places it at the intersection of these clusters.

What do the claim elements imply for design-arounds?

Design-around strategies typically aim to break one of the hard claim elements:

Avoid SEQ ID NO:2 backbone
If the competitor uses a different D. farinae allergen than SEQ ID NO:2, the claim is not triggered.
Miss the fragment length
Avoid using 10-34 residue fragments derived from SEQ ID NO:2 (e.g., use shorter epitopes, longer fragments outside the band, or non-derived peptide scaffolds).
Break the identity/mutation rules
Use variants with <90% identity and also outside the “1-10 substitutions/deletions plus additions” envelope.
Break “allergenicity”
If the competitor uses sequences that have intentionally reduced allergenicity such that they no longer meet the functional allergenicity requirement, the claim language may not read on those molecules.

In practice, many developers aim to avoid “exactly” the claimed antigen, then leverage distinct epitopes or different allergens. Because the claim ties the antigen identity to SEQ ID NO:2 with generous variant rules, the safest path is usually a different allergen target rather than an engineered variation of the same anchor.

What does this patent try to do that earlier patents often also do?

The claims mirror common allergy-patent goals but the “how” differs in the degree of anchoring:

Many older patents cover “D. farinae allergens” at a generic level.
US 10,457,711 narrows coverage by anchoring to SEQ ID NO:2 and then broadens again via:
- permissive variant space,
- and a defined peptide fragment window (10-34).

That mix increases enforceability against products that stay within the sequence universe around SEQ ID NO:2, but it also increases invalidity risk if SEQ ID NO:2 is already disclosed and if the therapeutic or diagnostic approach is routine.

Key data extraction from the claim set provided

Claim matrix

Claim	Endpoint	Administered antigen category	Sequence constraints	Fragment constraint
1	Prevent or treat D. farinae allergy	(a) SEQ ID NO:2 protein; (b) variant retaining allergenicity; (c) ≥90% identity variant retaining allergenicity	(b) 1-10 substitutions/deletions + additions; (c) ≥90% identity	10-34 residues of (a)-(c)
2	Detect D. farinae allergic state	Same (a)-(c) and fragments	Same	Same
3-6	Claim 1 refined	(a), (b), (c), or fragments	Same	10-34 residues
7-10	Claim 2 refined	(a), (b), (c), or fragments	Same	10-34 residues

What should business decision-makers watch next?

Confirm what SEQ ID NO:2 is in the full specification. If it corresponds to a well-known, already-published D. farinae allergen, the prior art risk increases for both anticipation and obviousness.
Check whether the patent defines allergenicity with an assay (IgE binding, basophil activation, skin prick compatibility, etc.). If the specification does not tie “allergenicity” to a reproducible standard, the claim becomes easier to attack.
Map competitor molecules to the exact claim boundaries:
- is there exact SEQ ID NO:2 usage?
- do variants meet “1-10 changes” and “allergenicity”?
- do diagnostics rely on administered 10-34mers derived from SEQ ID NO:2?

Key Takeaways

US 10,457,711 claims two method families: treatment/prevention (Claim 1) and detection (Claim 2), both anchored to SEQ ID NO:2 for D. farinae allergy.
The antigen scope is broad via variant allowances (1-10 substitutions/deletions + additions and ≥90% identity) and broad via peptide fragments (10-34 residues), but is functionally narrowed by the requirement that variants have D. farinae allergenicity.
The patent increases infringement surface area by covering both therapeutic and diagnostic methods with the same antigen set.
Validity pressure is most likely where SEQ ID NO:2 is already disclosed in prior art and where using homologous proteins or fragments for allergy therapy/diagnosis is established.

FAQs

1) Do Claims 1 and 2 cover both proteins and peptides?

Yes. Both claims include full-length proteins (SEQ ID NO:2; variants) and fragment peptides of 10 to 34 amino acid residues derived from those proteins.

2) Is the variant scope limited to substitutions only?

No. Claim 1 allows 1 to 10 substitutions or deletions, and also allows one or several amino acids added, relative to SEQ ID NO:2, provided allergenicity remains.

3) What is the identity threshold for category (c)?

Category (c) requires proteins with 90% or higher identity to the SEQ ID NO:2 sequence, with D. farinae allergenicity.

4) How is the detection method different from treatment?

Claim 2 requires administering the antigen to a test subject and measuring an allergic state. Claim 1 focuses on preventing or treating a D. farinae allergic disease in a patient.

5) What is the most practical design-around lever?

Avoid using molecules that fall within the SEQ ID NO:2 anchored sequence space (including the 10-34 residue fragment window) or ensure variants do not satisfy the “allergenicity of D. farinae” functional requirement.

References

[1] US Patent 10,457,711 claim set (user-provided text).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Greer Laboratories, Inc.	N/A	insects (whole body), mite dermatophagoides farinae	Injection	101834	September 15, 1958	10,457,711	2035-12-01
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,457,711

Summary for Patent: 10,457,711